Nestle gets closer to Seres, pledging $525m for microbiome C. diff drugSwiss food giant Nestle has firmed up its five-year-old alliance with US microbiome specialist Seres, paying $175 million Share XNestle gets closer to Seres, pledging $525m for microbiome C. diff drughttps://pharmaphorum.com/news/nestle-gets-closer-to-seres-pledging-525m-for-microbiome-c-diff-drug/
AZ joins with Seres to research role of gut microbiome in cancerAstraZeneca has announced an immuno-oncology collaboration with US biotech Seres Therapeutics, which will focus on increasing understanding of Share XAZ joins with Seres to research role of gut microbiome in cancerhttps://pharmaphorum.com/news/az-joins-with-seres-to-research-role-of-gut-microbiome-in-cancer/
